Abstract | Objectives: To compare best corrected visual acuity (BCVA), central macular thickness (CMT), and central choroidal thickness (CCT) in patients with type 2 macular telangiectasia (MacTel 2) and a control group and to evaluate the efficacy of intravitreal anti- vascular endothelial growth factor (anti- VEGF) treatment in MacTel 2 patients with macular neovascularization (MNV). Materials and Methods: We conducted a retrospective chart review of consecutive MacTel 2 patients who underwent a full ophthalmologic examination including BCVA and dilated fundus examination with slit-lamp biomicroscopy, fluorescein angiography, and optical coherence tomography imaging at baseline and follow-up visits. BCVA, CMT, and CCT were compared between all identified patients (n=26) and a control group ( n=30). A subgroup analysis was performed among eyes with MNV (n=7) before and after treatment. Results: CMT and CCT were significantly lower in the MacTel 2 group compared to the control group. Forty-one treatment-naive eyes without MNV proliferation showed no significant change in BCVA, CMT, or CCT during follow-up. Eight eyes of 7 MacTel 2 patients developed MNV during follow-up. All of the patients were treated with intravitreal anti- VEGF. Conclusion: It is important to closely follow MacTel 2 patients for MNV development. To avoid adverse effects, we prefer to monitor patients who have not yet developed MNV. Patients with proliferative MacTel 2 with decreasing visual function may benefit from intravitreal anti- VEGF treatment.
|
Authors | Müge Çoban Karataş, Gürsel Yılmaz, Aslıhan Yüce Sezen, Çağla Sarıtürk |
Journal | Turkish journal of ophthalmology
(Turk J Ophthalmol)
Vol. 52
Issue 1
Pg. 45-49
(02 23 2022)
ISSN: 2149-8709 [Electronic] Turkey |
PMID | 35196839
(Publication Type: Journal Article)
|
Topics |
- Diabetic Retinopathy
(drug therapy)
- Fluorescein Angiography
(methods)
- Humans
- Retrospective Studies
- Telangiectasis
- Visual Acuity
|